Categories Consumer

Luckin Coffee is already pleasing Wall Street analysts

This Chinese company is hardly two years old, it went public less than a month ago, and is already getting on the good side of Wall Street analysts. We are talking about Luckin Coffee (NASDAQ: LK), which, despite being smaller in size, is fast becoming a major competitor to Starbucks (NASDAQ: SBUX).

The company offers heavy discounts on its coffee, which can be ordered through a mobile app. Its shares have gained 5.6% since the IPO on May 16, when 33 million shares were offered at a price of $17 apiece.

luckin coffee
Image: Luckin Coffee

Three analysts have already expressed positive opinion on the stock. Eric Gonzalez of KeyBanc has rated the stock overweight, as he feels the low-budget model and limited competition in the home market will work in favor of the company.

“Luckin Coffee’s rapid ascent toward becoming one of China’s largest consumer brands has attracted its fair share of skeptics. However, we believe the company has several strategic advantages that should support its transition into a profitable business,” he said.

KeyBlanc has a price target of $22 on the stock, which is at a 22% upside from the last close.

READ: Chewy is going public on Friday and investors are thrilled

Meanwhile, Needham analyst Vincent Yu sees the company breaking even as early as the third quarter of this year. However, he does not expect cash-flow break-even until another year.

Needham has a better price target of $27, with a buy rating.

Lillian Lou of Morgan Stanley said, “We expect Luckin’s implied market share to grow from 1% to 23% in 2018-21. Urbanization and the increasing adoption of coffee-drinking by younger generations will underpin this growth.”

However, he warns that the company’s success could depend on a lot of factors including the rising competition, management strategy, and consumer demands. Morgan Stanley has a more cautious price target of $21 on the stock.

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top